Overview
- Lilly shares rose about 1.6% on Friday, lifting its market value to roughly $1 trillion and marking a first for a healthcare company, according to Bloomberg data.
- The company reported $17.6 billion in third-quarter revenue, with roughly 57% coming from obesity and diabetes treatments.
- Mounjaro generated about $6.52 billion and Zepbound about $3.59 billion in the quarter, reflecting triple-digit year-over-year growth.
- Lilly plans to file for FDA approval of its oral GLP-1, orforglipron, by year-end, and analysts project potential peak sales above $40 billion.
- Lilly has gained share over Novo Nordisk after Wegovy supply constraints and stronger efficacy findings, while rivals escalate efforts such as Pfizer’s $10 billion acquisition of Metsera.